Mar. 2 at 8:47 PM
$SNTI is a synthetic biology / CAR-NK cell therapy biotech trading at
$0.93 with a
$24.4M market cap. The cash position shows negative
$5.1M with negative 1.2 months of runway. This is a company in an active cash crisis burning
$12.19M per quarter.
Financing Details
The December 2024 financing was the lifeline. Two tranches of convertible preferred at
$2.25/share through Leerink, raising a combined
$47.6M. The first tranche was
$37.6M with investors Celadon, NEA, Bayer, Nantahala, and Red Hook. The second tranche was
$10M with investors Celadon, New Enterprise Associates, Bayer, Nantahala, Red Hook, Armistice, CVI, Blackwell, Empery, and PharmaEssentia. All
$47.6M has been fully converted into 21.15M shares. Attached to these raises were 31.7M warrants at
$2.30 expiring December 2029, held by the same investor group through Leerink.
The ATM with Leerink has
$16.8M remaining but is constrained by baby shelf restrictions. The stock needs to reach
$5.73 to lift those restrictions, against a current price of
$0.93. Effectively unusable right now. The Chardan equity line expired August 2025. Only
$4.36M is currently raisable under the shelf.
Two small ATM draws:
$550K at
$3.53 in June 2025 and
$150K at
$1.68 in September 2025 through Leerink, confirming the baby shelf ceiling is actively limiting raises.
An
$8M non-dilutive CIRM grant is supporting SENTI-202 clinical development, providing meaningful runway without shareholder dilution.
Bottom Line
Scientifically credible with serious institutional backing, but the cash math does not work at current burn without a new raise, a partnership, or significant cost cuts. The baby shelf wall at
$5.73 makes conventional capital markets access nearly impossible at today's price.
Not financial advice. Please consult a professional before making any investment decisions.
